Literature DB >> 23078921

Comparative analysis of traditional and coiled fiducials implanted during EUS for pancreatic cancer patients receiving stereotactic body radiation therapy.

Mouen A Khashab1, Katherine J Kim, Erik J Tryggestad, Aaron T Wild, Teboh Roland, Vikesh K Singh, Anne Marie Lennon, Eun Ji Shin, Mark A Ziegler, Reem Z Sharaiha, Marcia Irene Canto, Joseph M Herman.   

Abstract

BACKGROUND: EUS-guided fiducial placement facilitates image-guided radiation therapy (IGRT).
OBJECTIVE: To compare 2 types of commercially available fiducials for technical success, complications, visibility, and migration.
DESIGN: Retrospective, single-center, comparative study.
SETTING: Tertiary-care medical center.
INTERVENTIONS: Traditional fiducials (TFs) (5-mm length, 0.8-mm diameter) and Visicoil fiducials (VFs) (10-mm length, 0.35-mm diameter) were compared. Fiducials were placed using linear 19-gauge (for TFs) or 22-gauge (for VFs) needles. A subjective visualization scoring system (0-2; 0 = not visible, 1 = barely visible, 2 = clearly visible) was used to assess visibility on CT. Fiducial migration was calculated as a change in interfiducial distance. MAIN OUTCOME MEASUREMENTS: Technical success, complications, visibility, and migration of 2 types of fiducials.
RESULTS: Thirty-nine patients with locally advanced pancreatic cancer underwent EUS-guided placement of 103 fiducials (77 TFs, 26 VFs). The mean number of fiducials placed per patient was 2.66 (standard deviation 0.67) for the 19-gauge needle and 2.60 (standard deviation 0.70) for the 22-gauge needle (P = .83). No intra- or postprocedural complications were encountered. The median visibility score for TFs was significantly better than that for VFs, both when scores of 0 were and were not included (2.00, interquartile range [IQR] 2.00-2.00 vs 1.75, IQR 1.50-2.00, P = .009 and 2.00, IQR 2.00-2.00 vs 2.00, IQR 1.50-2.00, P < .0001, respectively). The mean migration was not significantly different between the 2 types of fiducials (0.8 mm [IQR 0.4-1.6 mm] for TFs vs 1.3 mm [IQR 0.6-1.5 mm] for VFs; P = .72). LIMITATIONS: Retrospective, nonrandomized design.
CONCLUSIONS: Visibility was significantly better for TFs compared with VFs. The degree of fiducial migration was not significantly different for TFs and VFs. There was no significant difference in the mean number of fiducials placed, indicating a similar degree of technical difficulty for TF and VF deployment.
Copyright © 2012 American Society for Gastrointestinal Endoscopy. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23078921      PMCID: PMC3578307          DOI: 10.1016/j.gie.2012.07.006

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  23 in total

1.  Daily electronic portal imaging of implanted gold seed fiducials in patients undergoing radiotherapy after radical prostatectomy.

Authors:  Daniel C Schiffner; Alexander R Gottschalk; Michael Lometti; Michele Aubin; Jean Pouliot; Joycelyn Speight; I-Chow Hsu; Katsuto Shinohara; Mack Roach
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-02-01       Impact factor: 7.038

2.  EUS-guided fiducial placement for image-guided radiation therapy in GI malignancies by using a 22-gauge needle (with videos).

Authors:  Christopher J DiMaio; Satish Nagula; Karyn A Goodman; Alice Y Ho; Arnold J Markowitz; Mark A Schattner; Hans Gerdes
Journal:  Gastrointest Endosc       Date:  2010-06       Impact factor: 9.427

3.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

Authors:  H A Burris; M J Moore; J Andersen; M R Green; M L Rothenberg; M R Modiano; M C Cripps; R K Portenoy; A M Storniolo; P Tarassoff; R Nelson; F A Dorr; C D Stephens; D D Von Hoff
Journal:  J Clin Oncol       Date:  1997-06       Impact factor: 44.544

4.  An assessment of clinically optimal gold marker length and diameter for pelvic radiotherapy verification using an amorphous silicon flat panel electronic portal imaging device.

Authors:  A M Henry; J Stratford; J Davies; C McCarthy; R Swindell; J Sykes; C J Moore; P Price; V S Khoo
Journal:  Br J Radiol       Date:  2005-08       Impact factor: 3.039

5.  Cancer statistics, 2001.

Authors:  R T Greenlee; M B Hill-Harmon; T Murray; M Thun
Journal:  CA Cancer J Clin       Date:  2001 Jan-Feb       Impact factor: 508.702

6.  Surgical morbidity, mortality, and long-term survival in patients with peripancreatic cancer following pancreaticoduodenectomy.

Authors:  J Stephens; J Kuhn; J O'Brien; J Preskitt; H Derrick; T Fisher; R Fuller; Z Lieberman
Journal:  Am J Surg       Date:  1997-12       Impact factor: 2.565

7.  Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer.

Authors:  Albert C Koong; Erin Christofferson; Quynh-Thu Le; Karyn A Goodman; Anthony Ho; Timothy Kuo; James M Ford; George A Fisher; Ralph Greco; Jeffrey Norton; George P Yang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-10-01       Impact factor: 7.038

8.  EUS-guided fiducial placement for CyberKnife radiotherapy of mediastinal and abdominal malignancies.

Authors:  Aline Charabaty Pishvaian; Brian Collins; Gregory Gagnon; Sushil Ahlawat; Nadim G Haddad
Journal:  Gastrointest Endosc       Date:  2006-09       Impact factor: 9.427

9.  Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies.

Authors:  Florence Huguet; Thierry André; Pascal Hammel; Pascal Artru; Jacques Balosso; Frédéric Selle; Elisabeth Deniaud-Alexandre; Philippe Ruszniewski; Emmanuel Touboul; Roberto Labianca; Aimery de Gramont; Christophe Louvet
Journal:  J Clin Oncol       Date:  2007-01-20       Impact factor: 44.544

10.  Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group.

Authors:  C G Moertel; S Frytak; R G Hahn; M J O'Connell; R J Reitemeier; J Rubin; A J Schutt; L H Weiland; D S Childs; M A Holbrook; P T Lavin; E Livstone; H Spiro; A Knowlton; M Kalser; J Barkin; H Lessner; R Mann-Kaplan; K Ramming; H O Douglas; P Thomas; H Nave; J Bateman; J Lokich; J Brooks; J Chaffey; J M Corson; N Zamcheck; J W Novak
Journal:  Cancer       Date:  1981-10-15       Impact factor: 6.860

View more
  32 in total

Review 1.  Endoscopic ultrasound guided interventional procedures.

Authors:  Vishal Sharma; Surinder S Rana; Deepak K Bhasin
Journal:  World J Gastrointest Endosc       Date:  2015-06-10

2.  Endoscopic Ultrasound-Guided Fiducial Placement for Gastrointestinal Malignancies.

Authors:  Manoop S Bhutani; Joseph M Herman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2019-03

3.  The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience.

Authors:  Shalini Moningi; Avani S Dholakia; Siva P Raman; Amanda Blackford; John L Cameron; Dung T Le; Ana M C De Jesus-Acosta; Amy Hacker-Prietz; Lauren M Rosati; Ryan K Assadi; Shirl Dipasquale; Timothy M Pawlik; Lei Zheng; Matthew J Weiss; Daniel A Laheru; Christopher L Wolfgang; Joseph M Herman
Journal:  Ann Surg Oncol       Date:  2015-01-07       Impact factor: 5.344

Review 4.  Endoscopic ultrasound in pancreatic cancer: innovative applications beyond the basics.

Authors:  Joseph Yoo; C Andrew Kistler; Linda Yan; Andrew Dargan; Ali A Siddiqui
Journal:  J Gastrointest Oncol       Date:  2016-12

Review 5.  Applications of endoscopic ultrasound in pancreatic cancer.

Authors:  Leticia Perondi Luz; Mohammad Ali Al-Haddad; Michael Sai Lai Sey; John M DeWitt
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

Review 6.  Endoscopic ultrasound-guided treatments: are we getting evidence based--a systematic review.

Authors:  Carlo Fabbri; Carmelo Luigiano; Andrea Lisotti; Vincenzo Cennamo; Clara Virgilio; Giancarlo Caletti; Pietro Fusaroli
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

7.  Interventional endoscopic ultrasonography.

Authors:  Lorenzo Fuccio; Fabia Attili; Giuseppe Vanella; Alberto Larghi
Journal:  Curr Treat Options Gastroenterol       Date:  2014-06

8.  Markerless Pancreatic Tumor Target Localization Enabled By Deep Learning.

Authors:  Wei Zhao; Liyue Shen; Bin Han; Yong Yang; Kai Cheng; Diego A S Toesca; Albert C Koong; Daniel T Chang; Lei Xing
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-06-13       Impact factor: 7.038

Review 9.  Recent progress in pancreatic cancer.

Authors:  Christopher L Wolfgang; Joseph M Herman; Daniel A Laheru; Alison P Klein; Michael A Erdek; Elliot K Fishman; Ralph H Hruban
Journal:  CA Cancer J Clin       Date:  2013-07-15       Impact factor: 508.702

10.  Evaluation of a Novel Absorbable Radiopaque Hydrogel in Patients Undergoing Image Guided Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.

Authors:  Avani Dholakia Rao; Eun Ji Shin; Jeffrey Meyer; Elizabeth L Thompson; Wei Fu; Chen Hu; Elliot K Fishman; Matthew Weiss; Christopher Wolfgang; Richard Burkhart; Jin He; Tossapol Kerdsirichairat; Joseph M Herman; Kai Ding; Amol Narang
Journal:  Pract Radiat Oncol       Date:  2020-03-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.